Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

INTRODUCTION: There are two treatment strategies for non-small cell lung cancer (NSCLC) exhibiting a high expression level of programmed death-ligand 1 (tumor proportion score ≥ 50%): pembrolizumab plus chemotherapy and monotherapy. We retrospectively compared their efficacy and safety. MATERIALS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Takumida, Hiroshi, Horinouchi, Hidehito, Masuda, Ken, Shinno, Yuki, Okuma, Yusuke, Yoshida, Tatsuya, Goto, Yasushi, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854243/
https://www.ncbi.nlm.nih.gov/pubmed/34389874
http://dx.doi.org/10.1007/s00262-021-03029-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854243/
https://www.ncbi.nlm.nih.gov/pubmed/34389874
http://dx.doi.org/10.1007/s00262-021-03029-9

Ejemplares similares